- ICH GCP
- Register voor klinische proeven in de VS.
- Klinische proef NCT03061058
Individualized Intraperitoneal and System Chemotherapy Versus System Chemotherapy as First-line Chemotherapy for AGC
An Open-label, Randomized, Phase III, Multicenter Clinical Trial Comparing the Efficacy and Safety of Individualized Intraperitoneal and System Chemotherapy Versus System Chemotherapy as First-line Chemotherapy for Advanced Gastric Cancer
Tumor messenger ribonucleic acid (mRNA) expression levels may have a promising role as potential predictive biomarkers for chemotherapy.
Peritoneal carcinomatosis appears to be the most common pattern of metastasis or recurrence and is associated with poor prognosis in gastric cancer patients. Intraperitoneal chemotherapy is widely accepted strategy in the treatment of peritoneal dissemination.
In this study, our aim is to evaluate the impact of individualized selection of chemotherapeutics and intraperitoneal combined with system chemotherapy on overall survival, disease free survival, response rate, and safety of advanced gastric cancer patients.
Studie Overzicht
Toestand
Studietype
Inschrijving (Verwacht)
Fase
- Fase 3
Contacten en locaties
Studie Locaties
-
-
Anhui
-
Ma'anshan, Anhui, China
- Werving
- Ma'anshan People's Hospital
-
Contact:
- Fenglin Zhang, MD
-
Contact:
- Fangbo Cui, MD
-
-
Jiangsu
-
Jiangyin, Jiangsu, China
- Werving
- Jiangyin People's Hospital
-
Contact:
- Weisheng Shen, MD
-
Contact:
- Lei Xi, MD
-
Nanjing, Jiangsu, China, 210008
- Werving
- The Comprehensive Cancer Center of Nanjing Drum Tower Hospital
-
Contact:
- Baorui Liu, MD, PhD
- Telefoonnummer: 0086-13770621908
- E-mail: baoruiliu07@163.com
-
Nanjing, Jiangsu, China, 210000
- Werving
- Nanjing Gaochun People's Hospital
-
Contact:
- Rongfu Wei, MD
-
Contact:
- Yajun Xin, MD
-
Nanjing, Jiangsu, China, 210000
- Werving
- Nanjing Lishui People's Hospital
-
Contact:
- Chunlan Nie, MD
-
Contact:
- Hui Xu, MD
-
Suqian, Jiangsu, China
- Werving
- Suqian People's Hospital
-
Contact:
- Chuanwen You, MD
-
Contact:
- Qing Zhu, MD
-
Xuzhou, Jiangsu, China
- Werving
- Xuzhou Central Hospital
-
Contact:
- Sanyuan Sun, MD
-
Zhenjiang, Jiangsu, China
- Werving
- Affiliated Hospital of Jiangsu University
-
Contact:
- Xiaoqing Li, MD
-
Contact:
- Meilian Cheng, MD
-
-
Deelname Criteria
Geschiktheidscriteria
Leeftijden die in aanmerking komen voor studie
Accepteert gezonde vrijwilligers
Geslachten die in aanmerking komen voor studie
Beschrijving
Inclusion Criteria:
- Patients must have histologically confirmed adenocarcinoma of the stomach or gastro-oesophageal junction with inoperable locally advanced or metastatic disease, not amenable to curative therapy.
- Patients must have measurable disease, according to the Response Evaluation Criteria in Solid Tumors (RECIST, v1.1), assessed using imaging techniques (CT or MRI).
- Patients must have enough tumor tissue for mRNA expression test.
- Women of childbearing potential must be non-pregnant (negative pregnancy test within 72 hours prior to chemotherapy, postmenopausal woman must have been amenorrheic for at least 12 months to be considered of non-childbearing potential) and nonlactating, and men and women must be willing to exercise an effective form of birth control (abstinence/contraception) while on study and for 6 months after therapy completed
- Eastern Cooperative Oncology Group (ECOG) Performance status 0, 1 or 2.
- Absolute neutrophil count (ANC) >=1,500/ul
- Platelets (PLT) >=75,000/ul
- Serum bilirubin <= 1.5 × upper limit of normal (ULN)
- Aspartate transaminase (AST) or alanine aminotransferase (ALT) <= 2.5 × ULN (or <= 5 × ULN in patients with liver metastases)
- Alkaline phosphatase <= 2.5 × ULN (or <= 5 × ULN in patients with liver metastases, or <= 10 × ULN in patients with bone but no liver metastases)
- Albumin >= 25 g/L.
- Creatinine clearance >= 60 mL/min.
- Life expectancy of at least 3 months.
- Signed informed consent.
Exclusion Criteria:
- Previous chemotherapy for advanced/metastatic disease (prior adjuvant/neoadjuvant therapy is allowed if at least 6 months has elapsed between completion of adjuvant/neoadjuvant therapy and enrolment into the study; the total dose of cisplatin should be less than 300mg/m^2).
- Patients with active (significant or uncontrolled) gastrointestinal bleeding.
- Residual relevant toxicity resulting from previous therapy (with the exception of alopecia), e.g. neurological toxicity ≥ grade 2 NCI-CTCAE 4.0.
- Other malignancy within the last 5 years, except for carcinoma in situ of the cervix, or basal cell carcinoma.
- History of documented congestive heart failure; angina pectoris requiring medication;evidence of transmural myocardial infarction on ECG; poorly controlled hypertension (systolic BP > 180 mmHg or diastolic BP > 100 mmHg); clinically significant valvular heart disease; or high risk uncontrollable arrhythmias.
- Baseline left ventricular ejection fraction (LVEF) < 50% (measured by echocardiography or MUGA).
- Patients with dyspnoea at rest due to complications of advanced malignancy or other disease, or who require supportive oxygen therapy.
- Patients receiving chronic or high dose corticosteroid therapy. (Inhaled steroids and short courses of oral steroids for anti-emesis or as an appetite stimulant are allowed).
- Clinically significant hearing abnormality.
- Known dihydropyrimidine dehydrogenase (DPD) deficiency.
- History or clinical evidence of brain metastases.
- Serious uncontrolled systemic intercurrent illness, e.g. infections or poorly controlled diabetes.
- Positive serum pregnancy test in women of childbearing potential.
- Received any investigational drug treatment within 4 weeks of start of study treatment.
- Radiotherapy within 4 weeks of start of study treatment (2 week interval allowed if palliative radiotherapy given to bone metastatic site peripherally and patient recovered from any acute toxicity;prior adjuvant radiotherapy is allowed if complete at least 6 months ).
- Major surgery within 4 weeks of start of study treatment, without complete recovery.
- Patients with known active infection with HIV, hepatitis B virus (HBV), or hepatitis C virus (HCV).
- Known hypersensitivity to any of the study drugs.
Studie plan
Hoe is de studie opgezet?
Ontwerpdetails
- Primair doel: Behandeling
- Toewijzing: Gerandomiseerd
- Interventioneel model: Parallelle opdracht
- Masker: Enkel
Wapens en interventies
Deelnemersgroep / Arm |
Interventie / Behandeling |
---|---|
Experimenteel: Individualized Group
mRNA levels of BRCA1, topoisomerase I (TOPO1), and thymidylate synthase (TS) were assessed in tumor tissue. Chemotherapeutic agents were selected based on the mRNA levels. Patients with high level BRCA1 will receive intraperitoneal docetaxel (15mg/m^2, d1, d15, q4w), intravenous docetaxel (30mg/m^2, d1, d15, q4w), and oral S-1 (40mg/m^2, d1-14, q4w). Patients with low level BRCA1 will receive intraperitoneal cisplatin (25mg/m^2, d1, d15, q4w), intravenous oxaliplatin (75mg/m^2, d1, d15, q4w), and oral S-1 (40mg/m^2, d1-14, q4w). Patients with middle level BRCA1 and high level TOPO1 will receive intraperitoneal irinotecan (45mg/m^2, d1, d15, q4w), intravenous docetaxel (90mg/m^2, d1, d15, q4w), and oral S-1 (40mg/m^2, d1-14, q4w). Patients with middle level BRCA1, low or middle level TOPO1, and low level TS will receive intraperitoneal pemetrexed (150mg/m^2, d1, q3w), and intravenous pemetrexed (350mg/m^2, d1, q3w). |
intraveneus
intraperitoneal and/or intravenous
intraperitoneal
intraperitoneal and/or intravenous
intraperitoneal and/or intravenous
oral
|
Actieve vergelijker: Control Group
mRNA levels of BRCA1, TOPO1, and TS were assessed in tumor tissue for every enrolled patients. Patients in control group will receive intravenous docetaxel (45mg/m^2, d1, d15, q4w), and oral S-1 (40mg/m^2, d1-14, q4w). |
intraperitoneal and/or intravenous
oral
|
Wat meet het onderzoek?
Primaire uitkomstmaten
Uitkomstmaat |
Maatregel Beschrijving |
Tijdsspanne |
---|---|---|
Progression-free Survival (PFS)
Tijdsspanne: up to 1 year
|
the follow-up visit of PFS will be performed every 6 weeks
|
up to 1 year
|
Secundaire uitkomstmaten
Uitkomstmaat |
Maatregel Beschrijving |
Tijdsspanne |
---|---|---|
Overall Survival (OS)
Tijdsspanne: up to 2 years
|
OS means that from the first dose of treatment drug to death or lost, the follow-up visit will be performed every 3 months till death or lost
|
up to 2 years
|
Objective Response Rate
Tijdsspanne: up to 24 weeks
|
CT/MRI will be performed every 2 cycles of treatment for efficacy evaluation
|
up to 24 weeks
|
Adverse Events
Tijdsspanne: up to 1 months
|
participants will be followed for the duration of hospital stay
|
up to 1 months
|
Medewerkers en onderzoekers
Studie record data
Bestudeer belangrijke data
Studie start (Werkelijk)
Primaire voltooiing (Verwacht)
Studie voltooiing (Verwacht)
Studieregistratiedata
Eerst ingediend
Eerst ingediend dat voldeed aan de QC-criteria
Eerst geplaatst (Werkelijk)
Updates van studierecords
Laatste update geplaatst (Werkelijk)
Laatste update ingediend die voldeed aan QC-criteria
Laatst geverifieerd
Meer informatie
Termen gerelateerd aan deze studie
Aanvullende relevante MeSH-voorwaarden
- Ziekten van het spijsverteringsstelsel
- Neoplasmata
- Neoplasmata per site
- Gastro-intestinale neoplasmata
- Neoplasmata van het spijsverteringsstelsel
- Gastro-intestinale aandoeningen
- Maag Ziekten
- Maagneoplasmata
- Moleculaire mechanismen van farmacologische werking
- Nucleïnezuursyntheseremmers
- Enzymremmers
- Antineoplastische middelen
- Tubuline-modulatoren
- Antimitotische middelen
- Mitose modulatoren
- Topoisomeraseremmers
- Topoisomerase I-remmers
- Foliumzuurantagonisten
- Docetaxel
- Oxaliplatine
- Irinotecan
- Pemetrexed
Andere studie-ID-nummers
- AGC-PC
Plan Individuele Deelnemersgegevens (IPD)
Bent u van plan om gegevens van individuele deelnemers (IPD) te delen?
Informatie over medicijnen en apparaten, studiedocumenten
Bestudeert een door de Amerikaanse FDA gereguleerd geneesmiddel
Bestudeert een door de Amerikaanse FDA gereguleerd apparaatproduct
product vervaardigd in en geëxporteerd uit de V.S.
Deze informatie is zonder wijzigingen rechtstreeks van de website clinicaltrials.gov gehaald. Als u verzoeken heeft om uw onderzoeksgegevens te wijzigen, te verwijderen of bij te werken, neem dan contact op met register@clinicaltrials.gov. Zodra er een wijziging wordt doorgevoerd op clinicaltrials.gov, wordt deze ook automatisch bijgewerkt op onze website .
Klinische onderzoeken op Oxaliplatine
-
SanofiVoltooid
-
Taiho Pharmaceutical Co., Ltd.Yakult Honsha Co., LTDVoltooidColorectale kankerJapan
-
Hebei Medical UniversityOnbekendMaagkanker | Lever metastaseChina
-
Universidad de LeónWervingLokaal gevorderde darmkankerSpanje
-
SanofiVoltooidMaagkankerKorea, republiek van
-
Wuhan Union Hospital, ChinaWervingVergevorderde maagkanker | Geavanceerde Gastro-oesofageale Junction AdenocarcinoomChina
-
QureBio Ltd.WervingGastro-oesofageale overgang (GEJ) AdenocarcinoomChina
-
Xijing HospitalWervingLokaal gevorderd adenocarcinoom van de maagChina
-
Kangbuk Samsung HospitalBeëindigdMaagkankerKorea, republiek van
-
Hebei Medical UniversityOnbekendLever metastase | HER-2 positieve maagkankerChina